New study tracks Real-World success of breast cancer drug in GCC
NCT ID NCT07597993
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study will follow about 109 women in Gulf Cooperation Council (GCC) countries who have a certain type of advanced breast cancer (HR-positive, HER2-low or ultra-low) and are taking the drug trastuzumab deruxtecan after hormone therapy stopped working. Researchers want to see how long the drug controls the cancer and what side effects occur in everyday medical practice, not just in a controlled trial. The goal is to learn how to best use this treatment in the region.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for BREAST CANCER are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Research Site
Abu Dhabi, United Arab Emirates
-
Research Site
Al Ain City, United Arab Emirates
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a Chest-Injected drug drain Cancer's fluid trap?
- A dab of gel on the breathing tube might spare surgery patients a sore throat — a trial puts it to the test.
- Can a deeper nerve block ease pain after breast surgery?
- Does breast cancer radiation harm a key immune gland? a study investigates
- A web program may ease the emotional toll of chemotherapy hair loss
- Can 3D breast imaging spot more dangerous cancers than standard mammograms?